At GSK, we understand this is a stressful and uncertain time for you and your loved ones. We also know that millions have relied on our non-steroidal anti-inflammatory (NSAIDs) products, including ibuprofen, for fast pain relief. That’s why we wanted to be sure to address some concerns we’ve heard surrounding the use of our NSAID products for the alleviation of COVID-19 symptoms.
Below is more information that may help you make informed decisions with your healthcare provider about what treatment might be best for your needs.
- Based on currently available information, WHO does not recommend against the use of ibuprofen.
- CDC is currently not aware of scientific evidence establishing a link between NSAIDs (e.g., ibuprofen, naproxen) and worsening of COVID 19.
- Researchers who raised an early hypothesis about ibuprofen for the treatment of COVID-19 have clarified it was meant for scientific consideration and was not intended to be a recommendation to use or not use certain medicines.
- Health Canada statement distributed on March 20, 2020 states, “There is no scientific evidence that establishes a link between ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs), and the worsening of COVID-19 symptoms.”
- We advise that people should speak directly with their doctor or healthcare provider if they have questions about their individual treatment needs.
Consumer safety is our No. 1 priority, and providing accurate information in times of uncertainty is key to achieving that.
Ibuprofen is a well-established medicine that has been used safely for many years as a fever reducer and to relieve pain and is strictly regulated to ensure it complies with local healthcare authority requirements. Our ibuprofen products are effectively used by millions of consumers across 40 markets and have been available as over-the-counter medicines for more than three decades.